Journal article
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer
Abstract
BACKGROUND: Linsitinib, an oral, dual inhibitor of insulin-like growth factor-1 receptor and insulin receptor, in combination with weekly paclitaxel, may improve clinical outcomes compared with paclitaxel alone in patients with refractory or platinum-resistant ovarian cancer.
PATIENTS AND METHODS: This open-label phase 1/2 clinical trial (NCT00889382) randomized patients with refractory or platinum-resistant ovarian cancer (1:1:1) to receive …
Authors
Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S
Journal
Gynecologic Oncology, Vol. 149, No. 2, pp. 275–282
Publisher
Elsevier
Publication Date
May 2018
DOI
10.1016/j.ygyno.2018.01.019
ISSN
0090-8258
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialDrug Administration ScheduleDrug Resistance, NeoplasmFemaleHumansImidazolesMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Glandular and EpithelialOrganoplatinum CompoundsOvarian NeoplasmsPaclitaxelPyrazinesTreatment OutcomeYoung Adult